导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.81% | 1329/4773 |
| 近一周 | -0.92% | 1395/5465 |
| 近一月 | -3.58% | 2651/5421 |
| 近一季 | -8.19% | 3155/5231 |
| 近半年 | -3.63% | 2527/4920 |
| 近一年 | 9.75% | 1169/4394 |
| 近两年 | 73.18% | 959/2954 |
| 近三年 | 40.62% | 748/2253 |
| 成立以来 | 94.79% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.71% 1204/4961 |
19.10% 1322/5312 |
- - |
- - |
| 2025 | 32.42% 1184/4813 |
2.20% 1438/3635 |
2.41% 1585/4076 |
24.52% 1457/4524 |
1.60% 1307/4813 |
| 2024 | 5.96% 1798/3463 |
-2.09% 1317/2808 |
-4.91% 1586/3014 |
14.92% 1875/3129 |
-0.98% 1558/3463 |
| 2023 | -5.66% 760/2656 |
7.52% 561/2280 |
-4.03% 1020/2385 |
-4.60% 1175/2515 |
-4.16% 894/2655 |
| 2022 | -17.40% 587/2207 |
-13.34% 739/1919 |
3.13% 1209/2016 |
-10.02% 336/2113 |
2.71% 855/2208 |
| 2021 | 17.49% 230/1822 |
-1.41% 485/1255 |
9.65% 540/1330 |
5.05% 299/1466 |
3.45% 431/1822 |
| 2020 | 24.26% 635/1250 |
-4.22% 345/1028 |
16.40% 442/1067 |
7.94% 753/1164 |
3.26% 930/1184 |
| 2019 | 25.78% 590/1092 |
30.36% 250/739 |
-9.59% 671/788 |
0.33% 530/850 |
6.37% 618/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.20% 424/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 平安500ETF联接C VS. 长安沪深300非周期A(740101) |